Beryllium

Hormone/ Element

Report in 12Hrs

At Home

No Fasting Required

Details

Heavy metal test for beryllium.

₹1,406₹2,009

30% OFF

Beryllium Test Information Guide

Why is it done?
- Measures beryllium levels in blood or urine to detect exposure to this toxic metal
- Screens for occupational exposure in workers from aerospace, electronics, dental prosthetics, metal recycling, and nuclear industries
- Detects chronic beryllium disease (CBD) and acute beryllium disease (ABD)
- Evaluates respiratory symptoms potentially related to beryllium inhalation
- Performed as baseline screening before employment or during periodic occupational health monitoring
- Assessed when workers report symptoms like cough, shortness of breath, chest tightness, or fatigue
Normal Range
- Blood Beryllium Levels: Less than 0.2 µg/L (micrograms per liter) or <2 µg/dL typically considered normal/background levels
- Beryllium Lymphocyte Proliferation Test (BeLPT): Negative result indicates no immunological sensitization to beryllium
- Urine Beryllium Levels: Less than 0.1-0.3 µg/L (varies by laboratory) is considered normal
- OSHA action level for workplace air exposure is 0.2 µg/m³ as an 8-hour time-weighted average
- Interpretation: Normal results indicate no detectable beryllium exposure or sensitization; abnormal results suggest occupational exposure or immune sensitization requiring further evaluation
Interpretation
- Negative BeLPT with Normal Blood Beryllium: Worker is not sensitized to beryllium; no evidence of chronic beryllium disease; low risk for CBD development
- Positive BeLPT (Sensitization): Indicates immune sensitization to beryllium; worker has developed abnormal immune response; does not definitively diagnose CBD but indicates increased risk; requires clinical correlation and further testing
- Elevated Blood Beryllium Levels: Suggests significant occupational exposure; combined with positive BeLPT indicates higher likelihood of developing or having CBD
- Chronic Beryllium Disease (CBD) Diagnosis: Requires positive BeLPT plus clinical/radiological evidence of pulmonary granulomatosis and history of beryllium exposure
- Acute Beryllium Disease (ABD): Occurs with high-level acute exposure; presents with acute respiratory symptoms and inflammation; BeLPT may be negative initially
- Factors Affecting Results: Duration and intensity of workplace exposure, workplace controls and ventilation, personal protective equipment usage, genetic predisposition (HLA-DP1 allele increases susceptibility), timing of testing relative to exposure
Associated Organs
- Primary Organ System: Respiratory system (lungs, bronchi, alveoli); immune system (lymphocytes, macrophages)
- Chronic Beryllium Disease (CBD): Progressive pulmonary granulomatosis; mimics sarcoidosis; causes progressive lung fibrosis; presents with progressive dyspnea, exercise intolerance, and respiratory insufficiency
- Acute Beryllium Disease (ABD): Acute chemical pneumonitis; beryllium-induced granulomatous lung disease; associated conditions include bronchitis, tracheobronchitis, and acute pulmonary edema
- Complications of Abnormal Results: Progressive respiratory failure, cor pulmonale (right heart failure from chronic lung disease), increased susceptibility to respiratory infections, oxygen dependency, premature mortality
- Associated Secondary Conditions: Hypercalcemia (from granulomatous disease), hypercalciuria, renal stones, tuberculosis risk (similar radiographic appearance), lung cancer risk (disputed but potential concern with long-term disease)
Follow-up Tests
- Chest X-ray (CXR) or High-Resolution CT (HRCT): Detects pulmonary granulomatosis, fibrosis patterns, and staging of CBD; initial diagnostic imaging when BeLPT positive
- Pulmonary Function Tests (PFTs): Spirometry, diffusion capacity (DLCO), lung volumes; assesses degree of respiratory impairment; baseline and periodic monitoring recommended
- Serum Calcium and 24-hour Urine Calcium: Screen for hypercalcemia/hypercalciuria complications from granulomatous disease
- Beryllium Urine Test: May be performed alongside blood testing to assess exposure and renal excretion
- Liver and Renal Function Tests: Assess organ function if hypercalcemia or chronic disease complications suspected
- HLA-DP1 Genetic Testing: May be useful for risk stratification; identifies workers with genetic susceptibility
- ACE Level and Angiotensin II: Elevated in granulomatous disease; help differentiate CBD from other conditions
- Monitoring Frequency for CBD: Annual or biennial BeLPT and pulmonary function testing for sensitized workers; repeat chest imaging as clinically indicated; more frequent monitoring with progressive disease
Fasting Required?
- Fasting Required: No
- Fasting is not required for beryllium testing; the test can be performed at any time of day
- Special Instructions:
- For blood beryllium test: Standard venipuncture protocols apply; use sterile, trace-metal-free collection tubes to prevent contamination
- For BeLPT (Beryllium Lymphocyte Proliferation Test): Requires blood sample; specialized laboratory handling required; sample must be processed within 24 hours; inform laboratory of test type to ensure proper processing
- For urine beryllium: Collect first-morning void or 24-hour urine as specified by laboratory; use clean, trace-metal-free containers provided by laboratory
- Medications: No specific medications need to be avoided; continue all regularly prescribed medications unless otherwise instructed by physician
- Workplace Considerations: Timing of test should be documented relative to last workplace exposure; if possible, blood samples should be collected during or shortly after shift work for occupational exposure assessment; workers should not shower or change clothes immediately before testing as this may affect exposure assessment
- Patient Information to Provide: History of occupational beryllium exposure, duration and intensity of exposure, types of protective equipment used, current respiratory symptoms, previous beryllium testing results if available

How our test process works!